• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Anticoagulation for Venous Thromboembolism: Impact on the Risk of Major Adverse Cardiovascular Events
Chest. 2022 Jun 14:S0012-3692(22)01087-X. doi: 10.1016/j.chest.2022.05.038. Online ahead of print.ABSTRACTBACKGROUND: It was recently established that patients who developed venous thromboembolism (VTE) are at increased risk of major adverse cardiovascular events (MACE) than the general population. However, whether the anticoagulation used for VTE influences the risk of MACE remains undescribed.RESEARCH QUESTION: Does the anticoagulant treatment for VTE impact the risk of subsequent MACE?STUDY DESIGN AND METHODS: We included patients from a large prospective cohort, who received only one family of anticoagulant treatment a...
Source: Chest - June 17, 2022 Category: Respiratory Medicine Authors: Steve Raoul Noumegni Raphael Le Mao Claire de Moreuil Cl ément Hoffmann Emmanuelle Le Moigne C écile Tromeur Vincent Mansourati Bahaa Nasr Md Jean-Christophe Gentric Marie Guegan Elise Poulhazan Luc Bressollette Karine Lacut Romain Didier Francis Coutur Source Type: research

Pulmonary Embolism
Pneumologie. 2021 Oct;75(10):800-818. doi: 10.1055/a-1029-9937. Epub 2021 Oct 18.ABSTRACTPulmonary embolism (PE) is a life-threatening disease and the third most frequent cardiovascular cause of death after stroke and myocardial infarction. The annual incidence is increasing (in Germany from 85 cases per 100000 population in the year 2005 to 109 cases per 100000 population in the year 2015). The individual risk for PE-related complications and death increases with the number of comorbidities and severity of right ventricular dysfunction. Using clinical, laboratory and imaging parameters, patients with PE can be stratified ...
Source: Pneumologie - October 18, 2021 Category: Respiratory Medicine Authors: Lukas Hobohm Mareike Lankeit Source Type: research

Comparing the Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in the Elderly Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
CONCLUSIONS: Compared to warfarin, NOACs were associated with a significantly lower risk of adverse events, with heterogeneity in treatment effects among different age strata. Overall, the clear safety signal in favor of NOACs over warfarin was evident irrespective of age strata, being most marked in the most elderly. PMID: 31809694 [PubMed - as supplied by publisher]
Source: Chest - December 2, 2019 Category: Respiratory Medicine Authors: Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GYH, Chen SA Tags: Chest Source Type: research

Direct acting oral anticoagulants (DOACs) in critically ill patients.
Abstract The direct acting oral anticoagulants (DOACs) have been increasingly utilized over vitamin K antagonists (VKA) in recent years because they do not require monitoring and have an immediate anti-coagulation effect. In general, DOACs have shown a better safety profile and non-inferiority for venous thromboembolism (VTE) prophylaxis and treatment, and stroke prevention in patients with atrial fibrillation, when compared to VKA agents in the non-ICU population. Whether this holds true in patients who are critically ill remains unknown. In this review, we will address the role of DOACs in special ICU population...
Source: Chest - June 24, 2019 Category: Respiratory Medicine Authors: Rali P, Gangemi A, Moores A, Mohrien K, Moores L Tags: Chest Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
CONCLUSIONS: Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs. PMID: 30472021 [PubMed - as supplied by publisher]
Source: Chest - November 22, 2018 Category: Respiratory Medicine Authors: Jung H, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B, Lip GYH Tags: Chest Source Type: research

Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
CONCLUSIONS: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s). PMID: 30144419 [PubMed - as supplied by publisher]
Source: Chest - August 21, 2018 Category: Respiratory Medicine Authors: Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, Lane DA, Ruff CT, Turakhia M, Werring D, Patel S, Moores L Tags: Chest Source Type: research

Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation.
Authors: Palleschi L, Nunziata E Abstract Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non-vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selectio...
Source: Monaldi Archives for Chest Disease - June 9, 2018 Category: Respiratory Medicine Tags: Monaldi Arch Chest Dis Source Type: research